dependence

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

The Central Problem

Source Node:
Time Stamp: November 21, 2022 1:09 AM - Modified On: November 21, 2022 - Published By:
Source Cluster:
Republished By Plato

The black swan events of LUNA and FTX that have so far characterized crypto in 2022 left many in the space wondering how we got here. What began as a quiet revolution focused on decentralization and financial sovereignty has been corrupted by greed and the centralization of power and control. If crypto has any hope of a future it can only be found in reaffirming the central tenets of decentralization and financial sovereignty. While the media claim these problems are the fault of a lack of regulation it’s worth considering